Risto-cel, Beam Therapeutics‘ single-dose, gene-edited cell therapy candidate for people with severe sickle cell disease (SCD), continues to…
Articles by Steve Bryson, PhD
Vascarta‘s VAS‑101, a skin gel containing curcumin — a component of the spice turmeric — was found in laboratory…
A new oral treatment, mitapivat, for sickle cell disease (SCD) significantly boosted hemoglobin levels in patients over a…
Researchers have identified a new method to reactivate fetal hemoglobin, without the need for gene-editing therapy, that has the potential…
The first sickle cell disease (SCD) patient has been enrolled in a Phase 1b clinical trial evaluating iadademstat,…
A Phase 1b clinical trial has exceeded the enrollment target for the group of adults with sickle cell disease…
The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment …
Changes in the gut microbiome, the group of bacteria and other microbes living in the digestive tract, may drive chronic…
Researchers have used an existing noninvasive optical tool that leverages the way light interacts with tissue to detect disease in…
Pfizer’s investigational therapy inclacumab failed to outperform a placebo in reducing the rate of vaso-occlusive crises — episodes…